Targeted CML therapy: controlling drug resistance, seeking cure

被引：139

作者：

O'Hare, T ^{[1
]}

Corbin, AS ^{[1
]}

Druker, BJ ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Inst Canc, Howard Hughes Med Inst, Portland, OR 97239 USA

来源：

CURRENT OPINION IN GENETICS & DEVELOPMENT | 2006年 / 16卷 / 01期

关键词：

D O I：

10.1016/j.gde.2005.11.002

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Targeted cancer therapy with imatinib (Gleevec) has the capability to drive chronic myeloid leukemia (CML) into clinical remission. Some patients, particularly those with advanced disease, develop resistance to imatinib. To counteract this problem, two new BCR-ABL kinase inhibitors for imatinib-refractory disease are currently in clinical trials: the imatinib derivative AMN107 and the dual-specificity SRC/ABL inhibitor dasatinib. Using imatinib to reduce leukemic burden also facilitates the detailed investigation into how the persistence of CML disease depends on BCR-ABL signaling, particularly within the leukemic stem cell compartment. Mathematical models of drug resistance and disease relapse, in addition to experimental systems that recapitulate crucial aspects of advanced disease have deepened our understanding of CML biology. Together, these advances are contributing to a high level of disease control, and might ultimately lead to disease eradication.

引用

页码：92 / 99

页数：8

共 58 条

[41] In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants [J].

O'Hare, T ;

Walters, DK ;

Stoffregen, EP ;

Jia, TP ;

Manley, PW ;

Mestan, J ;

Cowan-Jacob, SW ;

Lee, FY ;

Heinrich, MC ;

Deininger, MWN ;

Druker, BJ .

CANCER RESEARCH, 2005, 65 (11) :4500-4505

[42] BIRB-796 is not an effective ABL(T315I) inhibitor [J].

O'Hare, T ;

Druker, BJ .

NATURE BIOTECHNOLOGY, 2005, 23 (10) :1209-1210

[43] Combined AN inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib [J].

O'Hare, T ;

Walters, DK ;

Stoffregen, EP ;

Sherbenou, DW ;

Heinrich, MC ;

Deininger, MWN ;

Druker, BJ .

CLINICAL CANCER RESEARCH, 2005, 11 (19) :6987-6993

[44] Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML [J].

O'Hare, T ;

Pollock, R ;

Stoffregen, EP ;

Keats, JA ;

Abdullah, OM ;

Moseson, EM ;

Rivera, VM ;

Tang, H ;

Metcalf, CA ;

Bohacek, RS ;

Wang, YH ;

Sundaramoorthi, R ;

Shakespeare, WC ;

Dalgarno, D ;

Clackson, T ;

Sawyer, TK ;

Deininger, MW ;

Druker, BJ .

BLOOD, 2004, 104 (08) :2532-2539

[45]

OTTMANN O, 2005, P AN M AM SOC CLIN, V23, pS195

[46]

SAWYERS CL, 2005, P AN M AM SOC CLIN, V23, pS565

[47] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

[48] The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo [J].

Stover, EH ;

Chen, J ;

Lee, BH ;

Cools, J ;

McDowell, E ;

Adelsperger, J ;

Cullen, D ;

Coburn, A ;

Moore, SA ;

Okabe, R ;

Fabbro, D ;

Manley, PW ;

Griffin, JD ;

Gilliland, DG .

BLOOD, 2005, 106 (09) :3206-3213

[49] Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche [J].

Taichman, RS .

BLOOD, 2005, 105 (07) :2631-2639

[50]

Talpaz M, 2005, J CLIN ONCOL, V23, p564S

← 1 2 3 4 5 6 →